Pfizer submits COVID-19 vaccine trial data to FDA for children aged 5-11

Pfizer and BioNTech announced they have submitted results to the U.S. Food and Drug Administration from their coronavirus vaccine trial on children aged 5 to 11. According to a statement, the results showed a "favorable safety profile." Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center, joined CBSN to discuss.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting